Nicotinamide Gut-Targeted Composition for Post-COVID Symptom Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for active substances and compositions with minimal side effects to prevent or reduce post-acute symptoms of infectious diseases, particularly post-COVID syndrome (PCS), as interventions effective in the acute phase do not necessarily address long-term symptoms, and existing treatments may be ineffective against symptoms like impaired sense of smell and/or taste.
Innovation Solution
A composition comprising nicotinamide or its precursors and metabolites, formulated for topical supplementation in the lower small intestine and colon, is used to prevent or reduce post-acute symptoms by beneficially influencing the intestinal mucosa and microbiota, including symptoms such as impaired sense of smell and/or taste.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nicotinamide is used during the acute phase of infection, then acute symptoms are treated, but post-acute symptoms like impaired sense of smell and taste are not effectively addressed
Solution Approach 1:
The patent applies preliminary action by administering nicotinamide during the acute phase of infection to prevent and reduce post-acute symptoms that manifest later. The composition is given to patients during the acute phase before post-acute symptoms fully develop, establishing a preventive effect that addresses long-term outcomes rather than only treating immediate symptoms.
2Duration of action of stationary object
If conventional treatments are used during acute phase, then acute symptoms are managed, but long-term symptoms persist without effective intervention
Solution Approach 1:
The patent applies continuity of useful action by extending the therapeutic effect of nicotinamide administration beyond the acute phase. The composition is administered during the acute phase to maintain beneficial effects that continue into the post-acute period, ensuring continuous protection against symptom persistence rather than discontinuing treatment after acute symptoms resolve.
3Adaptability or versatility
If nicotinamide is administered systemically, then broad coverage is achieved, but specific topical effect in lower small intestine and colon is reduced
Solution Approach 1:
The patent applies local quality by formulating the nicotinamide composition to achieve both systemic coverage and localized effect in the lower small intestine and colon. The composition is designed with specific formulation characteristics that enable targeted delivery to the lower gastrointestinal tract where it can locally influence the mucosa and microbiota, while still providing adequate systemic absorption for broader therapeutic effects.
Data Source
AI summary
A composition comprising an active substance selected from nicotinamide; nicotinic acid; nicotinic acid esters; tryptophan; a tryptophan dipeptide; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, nicotinic acid mononucleotide (beta-nicotinate D-ribonucleotide), and nicotinic acid adenine dinucleotide; nicotinamide riboside; nicotinamide mononucleotide; 1-methylnicotinamide (N-methylnicotinamide); or a combination thereof, for use for preventing and/or reducing one or more post-acute symptoms of an infection, wherein the composition is formulated to partly or completely release the active substance(s), preferably nicotinamide, for topical supplementation or efficacy in the lower small intestine and/or the colon, wherein preferably the pathogen is SARS-CoV-2 and/or the post-acute symptoms are PCS